Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
- PMID: 33369366
- PMCID: PMC7781098
- DOI: 10.1056/NEJMoa2034545
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Abstract
Background: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear.
Methods: We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in seropositive and seronegative health care workers attending testing of asymptomatic and symptomatic staff at Oxford University Hospitals in the United Kingdom. Baseline antibody status was determined by anti-spike (primary analysis) and anti-nucleocapsid IgG assays, and staff members were followed for up to 31 weeks. We estimated the relative incidence of PCR-positive test results and new symptomatic infection according to antibody status, adjusting for age, participant-reported gender, and changes in incidence over time.
Results: A total of 12,541 health care workers participated and had anti-spike IgG measured; 11,364 were followed up after negative antibody results and 1265 after positive results, including 88 in whom seroconversion occurred during follow-up. A total of 223 anti-spike-seronegative health care workers had a positive PCR test (1.09 per 10,000 days at risk), 100 during screening while they were asymptomatic and 123 while symptomatic, whereas 2 anti-spike-seropositive health care workers had a positive PCR test (0.13 per 10,000 days at risk), and both workers were asymptomatic when tested (adjusted incidence rate ratio, 0.11; 95% confidence interval, 0.03 to 0.44; P = 0.002). There were no symptomatic infections in workers with anti-spike antibodies. Rate ratios were similar when the anti-nucleocapsid IgG assay was used alone or in combination with the anti-spike IgG assay to determine baseline status.
Conclusions: The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months. (Funded by the U.K. Government Department of Health and Social Care and others.).
Copyright © 2020 Massachusetts Medical Society.
Figures
Similar articles
-
SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.Microbiol Spectr. 2021 Oct 31;9(2):e0039121. doi: 10.1128/Spectrum.00391-21. Epub 2021 Sep 29. Microbiol Spectr. 2021. PMID: 34585976 Free PMC article.
-
Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark.Microbiol Spectr. 2021 Oct 31;9(2):e0090421. doi: 10.1128/Spectrum.00904-21. Epub 2021 Oct 20. Microbiol Spectr. 2021. PMID: 34668738 Free PMC article.
-
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.J Intern Med. 2022 Jan;291(1):72-80. doi: 10.1111/joim.13387. Epub 2021 Sep 27. J Intern Med. 2022. PMID: 34459525 Free PMC article.
-
Protein-based lateral flow assays for COVID-19 detection.Protein Eng Des Sel. 2021 Feb 15;34:gzab010. doi: 10.1093/protein/gzab010. Protein Eng Des Sel. 2021. PMID: 33991088 Free PMC article. Review.
-
Serological markers and long COVID-A rapid systematic review.Eur J Clin Invest. 2024 Apr;54(4):e14149. doi: 10.1111/eci.14149. Epub 2023 Dec 11. Eur J Clin Invest. 2024. PMID: 38083997 Review.
Cited by
-
Navigating the Landscape of B Cell Mediated Immunity and Antibody Monitoring in SARS-CoV-2 Vaccine Efficacy: Tools, Strategies and Clinical Trial Insights.Vaccines (Basel). 2024 Sep 24;12(10):1089. doi: 10.3390/vaccines12101089. Vaccines (Basel). 2024. PMID: 39460256 Free PMC article. Review.
-
The Trajectory of Antibody Responses One Year Following SARS-CoV-2 Infection among Indigenous Individuals in the Southwest United States.Viruses. 2024 Oct 5;16(10):1573. doi: 10.3390/v16101573. Viruses. 2024. PMID: 39459907 Free PMC article.
-
Time-course analysis of antibody and cytokine response after the third SARS-CoV-2 vaccine dose.Vaccine X. 2024 Sep 24;20:100565. doi: 10.1016/j.jvacx.2024.100565. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39399820 Free PMC article.
-
Antibody response to SARS-CoV-2 natural and breakthrough infection in patients undergoing maintenance hemodialysis: A prospective cohort study over 4 months.Heliyon. 2024 Sep 26;10(19):e38545. doi: 10.1016/j.heliyon.2024.e38545. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39397907 Free PMC article.
-
Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection.Front Immunol. 2024 Sep 17;15:1445653. doi: 10.3389/fimmu.2024.1445653. eCollection 2024. Front Immunol. 2024. PMID: 39355249 Free PMC article.
References
-
- Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008;47:401-409. - PubMed
-
- Lumley SF, Wei J, O’Donnell D, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. November 4, 2020. (https://www.medrxiv.org/content/10.1101/2020.11.02.20224824v1). preprint. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous